-Translational Cancer Imaging (TCI) Shared Resource The goal of the Translational Cancer Imaging (TCI) resource is to provide cancer center members with a comprehensive imaging service that will facilitate basic, clinical, as well as translational cancer research at UNC. The TCI has expanded from the original Small Animal Imaging Core to include four key units: 1) Cyclotron & Imaging Probe; 2) Preclinical Imaging; 3) Clinical Research Imaging; and 4) Image Analysis. The expansion of the imaging core will not only enhance our overall imaging capability, but also greatly expedite cancer research developed from basic science to clinical application with advanced tools and channels built within the TCI. The new Cyclotron and Imaging Probe unit contains all the equipment needed to support radiopharmaceutical development, clinical translation, and probe production for molecular imaging studies. Key components include state of the art radiochemistry research facility with a high energy (16.5 MeV) GE PETtrace cyclotron, multiple automated radiochemical processing modules, clean room, hot cells and other ancillary equipment. The Animal Imaging unit has a new mouse 3,000 cage holding unit and houses eleven pieces of imaging equipment dedicated for animal studies, including a 9.4T animal MR scanner, one animal PET/CT scanner, one SPECT/CT scanner, one high resolution microCT for specimens, one microCT systems for in vivo studies, two high resolution ultrasound system, three IVIS optical imaging systems, and one 3D tomographic fluorescence imaging system. With all the equipment located in one centralized space, the preclinical imaging unit is capable of providing non-invasive imaging, longitudinal studies, as well as multimodality imaging on animal models in various cancer applications. The Human Imaging unit is equipped with one 3T whole body MRI scanner, one integrated MRI/PET scanner, one PET/CT scanner, and one whole body 7T MRI scanner, all dedicated for clinical research. Again, they are all located in one centralized space right above the animal Imaging unit. These dedicated instruments strongly support the translational cancer research in a seamless fashion. The Image Analysis unit will continue to provide advanced analysis tools, customized software, and data storage and transfer tools to support imaging studies. For the next funding cycle, the TCI proposes two major aims, namely 1) to enhance infrastructure for imaging probe services and translational development; 2) strengthen animal and human imaging support in cancer research. We will enhance the infrastructure to provide imaging probe development and production services for both preclinical and clinical usage. Meanwhile, we will continue expanding our imaging capability, improving infrastructures for translational imaging study, and promoting human imaging research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016086-43
Application #
9614912
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2018-12-01
Budget End
2019-11-30
Support Year
43
Fiscal Year
2019
Total Cost
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Sun, Junjiang; Shao, Wenwei; Chen, Xiaojing et al. (2018) An Observational Study from Long-Term AAV Re-administration in Two Hemophilia Dogs. Mol Ther Methods Clin Dev 10:257-267
Wilczewski, Caralynn M; Hepperla, Austin J; Shimbo, Takashi et al. (2018) CHD4 and the NuRD complex directly control cardiac sarcomere formation. Proc Natl Acad Sci U S A 115:6727-6732
Waters, Andrew M; Der, Channing J (2018) KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer. Cold Spring Harb Perspect Med 8:
Cai, Ling; Tsai, Yi-Hsuan; Wang, Ping et al. (2018) ZFX Mediates Non-canonical Oncogenic Functions of the Androgen Receptor Splice Variant 7 in Castrate-Resistant Prostate Cancer. Mol Cell 72:341-354.e6
Moschos, Stergios J; Sullivan, Ryan J; Hwu, Wen-Jen et al. (2018) Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors. JCI Insight 3:
Brosnan, Evelyn M; Anders, Carey K (2018) Understanding patterns of brain metastasis in breast cancer and designing rational therapeutic strategies. Ann Transl Med 6:163
Valle, Carmina G; Queen, Tara L; Martin, Barbara A et al. (2018) Optimizing Tailored Communications for Health Risk Assessment: A Randomized Factorial Experiment of the Effects of Expectancy Priming, Autonomy Support, and Exemplification. J Med Internet Res 20:e63
Zhang, Jing; Wu, Tao; Simon, Jeremy et al. (2018) VHL substrate transcription factor ZHX2 as an oncogenic driver in clear cell renal cell carcinoma. Science 361:290-295
Zhang, Cun-Jin; Wang, Chenhui; Jiang, Meiling et al. (2018) Act1 is a negative regulator in T and B cells via direct inhibition of STAT3. Nat Commun 9:2745
Anderson, Chelsea; Engel, Stephanie M; Anders, Carey K et al. (2018) Live birth outcomes after adolescent and young adult breast cancer. Int J Cancer 142:1994-2002

Showing the most recent 10 out of 1525 publications